Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




HbA1C Blood Test Uncovers Undiagnosed Diabetes

By HospiMedica International staff writers
Posted on 31 May 2016
A new study reveals that the hemoglobin A1C (HbA1C) test can effectively detect hidden disease among hospital patients admitted with hyperglycemia.

Researchers from Touro University (Vallejo, CA, USA) and Ohio University Heritage College of Osteopathic Medicine (HCOM; Athens, USA) conducted a retrospective review of medical records of 348 patients admitted with hyperglycemia to examine the use of HbA1c tests in identifying previously undiagnosed diabetes mellitus. More...
Of those patients, 50 had no known history of diabetes, and among them 31 (62%) were given an HbA1C test.

The results showed that 77% of the patients had results consistent with diagnoses of diabetes (58 %) or prediabetes (19%). Seventeen (55%) of the 31 patients had a discharge diagnosis that included diabetes. Of the 19 patients with no known history of diabetes who did not have an HbA1c test, 2 (11%) received a discharge diagnosis that included diabetes. The study was published in the June 2016 issue of the Journal of the American Osteopathic Association.

“We are missing opportunities to detect diabetes and initiate treatment for those patients to help manage that disease, which can reduce their long-term cost of care and disease burden,” said senior author Professor Jay Shubrook, DO, of HCOM. “From the osteopathic perspective of early detection equals better outcomes, it's easy to make a case for hospital protocols to trigger an HbA1C test when hyperglycemia is detected to distinguish between transient hyperglycemia and chronic disease.”

HbA1c refers to glycated hemoglobin, and is used to identify the average plasma glucose concentration over 8-12 weeks. For people without diabetes, the normal HbA1c range is 4-5.6%. HbA1c levels between 5.7% and 6.4% indicate increased risk of diabetes, and levels of 6.5% or higher indicate diabetes. The goal for diabetics is HbA1c levels less than 7%, which should be retested every three months to determine target level control.

Related Links:
Touro University
Ohio University Heritage College of Osteopathic Medicine

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Portable Jaundice Management Device
Nymphaea
Isolation Stretcher
IS 736
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.